These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 7977232)

  • 1. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C.
    Hayashi J; Ohmiya M; Kishihara Y; Tani Y; Kinukawa N; Ikematsu H; Kashiwagi S
    Am J Gastroenterol; 1994 Dec; 89(12):2151-6. PubMed ID: 7977232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(4):319-24. PubMed ID: 8658063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in serum levels of hepatitis C virus genotype 1b monitored by real-time quantitative polymerase chain reaction as a predictor of long term response to interferon-alpha treatment.
    Enomoto M; Nishiguchi S; Shiomi S; Tanaka M; Yokogawa T; Fukuda K; Ueda T; Tamori A; Habu D; Takeda T; Yano Y; Otani S
    Am J Gastroenterol; 2002 Feb; 97(2):420-6. PubMed ID: 11866282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection.
    Chayama K; Tsubota A; Kobayashi M; Okamoto K; Hashimoto M; Miyano Y; Koike H; Kobayashi M; Koida I; Arase Y; Saitoh S; Suzuki Y; Murashima N; Ikeda K; Kumada H
    Hepatology; 1997 Mar; 25(3):745-9. PubMed ID: 9049229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleotide sequence variations in the internal ribosome entry site of hepatitis C virus-1b: no association with efficacy of interferon therapy or serum HCV-RNA levels.
    Yamamoto C; Enomoto N; Kurosaki M; Yu SH; Tazawa J; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Dec; 26(6):1616-20. PubMed ID: 9398006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy.
    Mazzaro C; Franzin F; Tulissi P; Pussini E; Crovatto M; Carniello GS; Efremov DG; Burrone O; Santini G; Pozzato G
    Cancer; 1996 Jun; 77(12):2604-13. PubMed ID: 8640712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection.
    Tsubota A; Chayama K; Ikeda K; Yasuji A; Koida I; Saitoh S; Hashimoto M; Iwasaki S; Kobayashi M; Hiromitsu K
    Hepatology; 1994 May; 19(5):1088-94. PubMed ID: 8175130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large dose natural interferon alpha therapy for patients with chronic hepatitis C.
    Ohmiya M; Hayashi J; Furusyo N; Ueno K; Kishihara Y; Nabeshima S; Kashiwagi S
    Fukuoka Igaku Zasshi; 1997 Dec; 88(12):380-8. PubMed ID: 9465478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients.
    Missale G; Cariani E; Lamonaca V; Ravaggi A; Rossini A; Bertoni R; Houghton M; Matsuura Y; Miyamura T; Fiaccadori F; Ferrari C
    Hepatology; 1997 Sep; 26(3):792-7. PubMed ID: 9303515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of a rapid negativity of serum virus C viremia during treatment with interferon alpha in patients with chronic hepatitis C].
    Moulin V; Harzic M; Doll J; Dubeaux B; Ghnassia JC; Andrieu J
    Pathol Biol (Paris); 1996 May; 44(5):468-72. PubMed ID: 8758497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors for efficacy of interferon therapy in chronic hepatitis type C.
    Ishibashi K; Kashiwagi T; Ito A; Tanaka Y; Nagata T; Tamaki J; Azuma M; Kishida Y; Yoshida A; Hikiji AY
    Hepatogastroenterology; 1995; 42(5):535-41. PubMed ID: 8751211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.